White Paper

Formulation Research Strategy For Discovery- Stage New Drug Candidates

By Jim Huang, PhD, Founder & CEO, and Edward Orton, PhD, SVP, Ascendia Pharmaceuticals

Computational Science: Disruption In Biopharma Discovery

Drug discovery medicinal chemistry programs typically involve generations of multiple lead compounds, which must be evaluated according to various selection criteria.

The selection process allows a drug candidate along with one or more backup candidates to be chosen for preclinical development from a set of lead compounds. Thus, in vivo studies of new drug candidates at this early stage take on great importance. Negative or ambiguous results may well lead to erroneous conclusions regarding candidate advancement. In worst case scenarios, research programs may be terminated based on flawed data.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online